424 related articles for article (PubMed ID: 8548755)
1. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
Ueki K; Ono Y; Henson JW; Efird JT; von Deimling A; Louis DN
Cancer Res; 1996 Jan; 56(1):150-3. PubMed ID: 8548755
[TBL] [Abstract][Full Text] [Related]
2. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
[TBL] [Abstract][Full Text] [Related]
3. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
[TBL] [Abstract][Full Text] [Related]
4. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
Dreyling MH; Bullinger L; Ott G; Stilgenbauer S; Müller-Hermelink HK; Bentz M; Hiddemann W; Döhner H
Cancer Res; 1997 Oct; 57(20):4608-14. PubMed ID: 9377576
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression.
Geradts J; Kratzke RA; Niehans GA; Lincoln CE
Cancer Res; 1995 Dec; 55(24):6006-11. PubMed ID: 8521382
[TBL] [Abstract][Full Text] [Related]
6. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
7. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.
Schmidt EE; Ichimura K; Reifenberger G; Collins VP
Cancer Res; 1994 Dec; 54(24):6321-4. PubMed ID: 7987821
[TBL] [Abstract][Full Text] [Related]
8. Chromosome 9p allelic loss and p16/CDKN2 in breast cancer and evidence of p16 inactivation in immortal breast epithelial cells.
Brenner AJ; Aldaz CM
Cancer Res; 1995 Jul; 55(13):2892-5. PubMed ID: 7796417
[TBL] [Abstract][Full Text] [Related]
9. Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines.
Sartor M; Steingrimsdottir H; Elamin F; Gäken J; Warnakulasuriya S; Partridge M; Thakker N; Johnson NW; Tavassoli M
Br J Cancer; 1999 Apr; 80(1-2):79-86. PubMed ID: 10389982
[TBL] [Abstract][Full Text] [Related]
10. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
Schultz DC; Vanderveer L; Buetow KH; Boente MP; Ozols RF; Hamilton TC; Godwin AK
Cancer Res; 1995 May; 55(10):2150-7. PubMed ID: 7743516
[TBL] [Abstract][Full Text] [Related]
11. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.
Schutte M; Hruban RH; Geradts J; Maynard R; Hilgers W; Rabindran SK; Moskaluk CA; Hahn SA; Schwarte-Waldhoff I; Schmiegel W; Baylin SB; Kern SE; Herman JG
Cancer Res; 1997 Aug; 57(15):3126-30. PubMed ID: 9242437
[TBL] [Abstract][Full Text] [Related]
12. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray.
Yin D; Ogawa S; Kawamata N; Tunici P; Finocchiaro G; Eoli M; Ruckert C; Huynh T; Liu G; Kato M; Sanada M; Jauch A; Dugas M; Black KL; Koeffler HP
Mol Cancer Res; 2009 May; 7(5):665-77. PubMed ID: 19435819
[TBL] [Abstract][Full Text] [Related]
13. Infrequent CDKN2 mutation in human differentiated thyroid cancers.
Tung WS; Shevlin DW; Bartsch D; Norton JA; Wells SA; Goodfellow PJ
Mol Carcinog; 1996 Jan; 15(1):5-10. PubMed ID: 8561866
[TBL] [Abstract][Full Text] [Related]
14. Increased p16 levels correlate with pRb alterations in human urothelial cells.
Yeager T; Stadler W; Belair C; Puthenveettil J; Olopade O; Reznikoff C
Cancer Res; 1995 Feb; 55(3):493-7. PubMed ID: 7834615
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma.
Okami K; Reed AL; Cairns P; Koch WM; Westra WH; Wehage S; Jen J; Sidransky D
Oncogene; 1999 Jun; 18(23):3541-5. PubMed ID: 10376532
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage.
Nakagawa K; Conrad NK; Williams JP; Johnson BE; Kelley MJ
Oncogene; 1995 Nov; 11(9):1843-51. PubMed ID: 7478613
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
18. p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells.
Jarrard DF; Sarkar S; Shi Y; Yeager TR; Magrane G; Kinoshita H; Nassif N; Meisner L; Newton MA; Waldman FM; Reznikoff CA
Cancer Res; 1999 Jun; 59(12):2957-64. PubMed ID: 10383161
[TBL] [Abstract][Full Text] [Related]
19. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth.
Arap W; Nishikawa R; Furnari FB; Cavenee WK; Huang HJ
Cancer Res; 1995 Mar; 55(6):1351-4. PubMed ID: 7882335
[TBL] [Abstract][Full Text] [Related]
20. Loss of P16INK4 expression is frequent in high grade gliomas.
Nishikawa R; Furnari FB; Lin H; Arap W; Berger MS; Cavenee WK; Su Huang HJ
Cancer Res; 1995 May; 55(9):1941-5. PubMed ID: 7728764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
